Bank of America’s Acrivon Therapeutics ACRV Stock Holding History

Bank of America’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23K	Sell	16,513 -934	-5%	-$1.63K	﹤0.01%	5645
2025 Q4	$42K	Sell	17,447 -1,457	-8%	-$3.17K	﹤0.01%	5886
2025 Q3	$34.2K	Sell	18,904 -1,713	-8%	-$2.41K	﹤0.01%	6941
2025 Q2	$24.5K	Sell	20,617 -7,082	-26%	-$9.72K	﹤0.01%	7008
2025 Q1	$56.2K	Sell	27,699 -3,407	-11%	-$18.3K	﹤0.01%	6705
2024 Q4	$187K	Buy	31,106 +1,143	+4%	+$8.31K	﹤0.01%	6150
2024 Q3	$210K	Buy	29,963 +2,413	+9%	+$19K	﹤0.01%	5980
2024 Q2	$160K	Buy	27,550 +21,511	+356%	+$173K	﹤0.01%	6008
2024 Q1	$43.2K	Sell	6,039 -4,049	-40%	-$18.8K	﹤0.01%	6566
2023 Q4	$49.6K	Buy	10,088 +756	+8%	+$3.99K	﹤0.01%	6597
2023 Q3	$89.2K	Buy	9,332 +1,708	+22%	+$19.7K	﹤0.01%	6297
2023 Q2	$98.8K	Buy	7,624 +1,768	+30%	+$21.4K	﹤0.01%	6208
2023 Q1	$74.3K	Buy	+5,856	New	+$98.3K	﹤0.01%	6364

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's ACRV Position: Q1 2026 in Review

Bank of America reduced its Acrivon Therapeutics (ACRV) stake by 5.4% in Q1 2026, selling an estimated $1.63K and leaving 16,513 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #5645.

Bank of America first reported a position in ACRV in Q1 2023 and has held it in 13 quarters since. The position peaked at $210K in Q3 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Bank of America held 16,513 shares of Acrivon Therapeutics worth $23K as of Q1 2026.
Bank of America sold 934 Acrivon Therapeutics shares in Q1 2026, an estimated $1.63K.
Acrivon Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5645 holding.
Bank of America first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 13 quarters since.
Bank of America's Acrivon Therapeutics position peaked at $210K in Q3 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.